• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

一项多中心前瞻性研究,评估术前 CT 扫描和血清 CA-125 预测晚期卵巢癌、输卵管癌和腹膜癌初次肿瘤细胞减灭术时非理想减瘤的能力。

A multicenter prospective trial evaluating the ability of preoperative computed tomography scan and serum CA-125 to predict suboptimal cytoreduction at primary debulking surgery for advanced ovarian, fallopian tube, and peritoneal cancer.

机构信息

Gynecology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center (MSKCC), New York, NY, USA.

Department of Gynecologic Oncology, MD Anderson Cancer Center (MDACC), Houston, TX, USA.

出版信息

Gynecol Oncol. 2014 Sep;134(3):455-61. doi: 10.1016/j.ygyno.2014.07.002. Epub 2014 Jul 11.

DOI:10.1016/j.ygyno.2014.07.002
PMID:25019568
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4387777/
Abstract

OBJECTIVE

To assess the ability of preoperative computed tomography (CT) scan of the abdomen/pelvis and serum CA-125 to predict suboptimal (>1cm residual disease) primary cytoreduction in advanced ovarian, fallopian tube, and peritoneal cancer.

METHODS

This was a prospective, non-randomized, multicenter trial of patients who underwent primary cytoreduction for stage III-IV ovarian, fallopian tube, and peritoneal cancer. A CT scan of the abdomen/pelvis and serum CA-125 were obtained within 35 and 14 days before surgery, respectively. Four clinical and 20 radiologic criteria were assessed.

RESULTS

From 7/2001 to 12/2012, 669 patients were enrolled; 350 met eligibility criteria. The optimal debulking rate was 75%. On multivariate analysis, three clinical and six radiologic criteria were significantly associated with suboptimal debulking: age ≥ 60 years (p=0.01); CA-125 ≥ 500 U/mL (p<0.001); ASA 3-4 (p<0.001); suprarenal retroperitoneal lymph nodes >1cm (p<0.001); diffuse small bowel adhesions/thickening (p<0.001); and lesions >1cm in the small bowel mesentery (p=0.03), root of the superior mesenteric artery (p=0.003), perisplenic area (p<0.001), and lesser sac (p<0.001). A 'predictive value score' was assigned for each criterion, and the suboptimal debulking rates of patients who had a total score of 0, 1-2, 3-4, 5-6, 7-8, and ≥ 9 were 5%, 10%, 17%, 34%, 52%, and 74%, respectively. A prognostic model combining these nine factors had a predictive accuracy of 0.758.

CONCLUSIONS

We identified nine criteria associated with suboptimal cytoreduction, and developed a predictive model in which the suboptimal rate was directly proportional to a predictive value score. These results may be helpful in pretreatment patient assessment.

摘要

目的

评估术前腹部/骨盆计算机断层扫描(CT)和血清 CA-125 预测晚期卵巢、输卵管和腹膜癌初始细胞减灭术不充分(残留病灶>1cm)的能力。

方法

这是一项针对接受 III-IV 期卵巢、输卵管和腹膜癌初始细胞减灭术的患者的前瞻性、非随机、多中心试验。在手术前 35 天和 14 天内分别获得腹部/骨盆 CT 扫描和血清 CA-125。评估了 4 项临床和 20 项影像学标准。

结果

从 2001 年 7 月至 2012 年 12 月,共纳入 669 例患者;其中 350 例符合入选标准。最佳减瘤率为 75%。多变量分析显示,3 项临床和 6 项影像学标准与不充分减瘤显著相关:年龄≥60 岁(p=0.01);CA-125≥500U/mL(p<0.001);ASA 3-4 级(p<0.001);肾上腺后腹膜淋巴结>1cm(p<0.001);弥漫性小肠粘连/增厚(p<0.001);以及小肠系膜病变>1cm(p=0.03)、肠系膜上动脉根部(p=0.003)、脾周区域(p<0.001)和小网膜囊(p<0.001)。为每个标准分配了“预测值评分”,总分为 0、1-2、3-4、5-6、7-8 和≥9 的患者的不充分减瘤率分别为 5%、10%、17%、34%、52%和 74%。结合这 9 个因素的预后模型预测准确率为 0.758。

结论

我们确定了与不充分细胞减灭相关的 9 个标准,并建立了一个预测模型,其中不充分率与预测值评分成正比。这些结果可能有助于术前患者评估。

相似文献

1
A multicenter prospective trial evaluating the ability of preoperative computed tomography scan and serum CA-125 to predict suboptimal cytoreduction at primary debulking surgery for advanced ovarian, fallopian tube, and peritoneal cancer.一项多中心前瞻性研究,评估术前 CT 扫描和血清 CA-125 预测晚期卵巢癌、输卵管癌和腹膜癌初次肿瘤细胞减灭术时非理想减瘤的能力。
Gynecol Oncol. 2014 Sep;134(3):455-61. doi: 10.1016/j.ygyno.2014.07.002. Epub 2014 Jul 11.
2
A multicenter assessment of the ability of preoperative computed tomography scan and CA-125 to predict gross residual disease at primary debulking for advanced epithelial ovarian cancer.一项关于术前计算机断层扫描和CA-125预测晚期上皮性卵巢癌初次肿瘤细胞减灭术时肉眼残留病灶能力的多中心评估。
Gynecol Oncol. 2017 Apr;145(1):27-31. doi: 10.1016/j.ygyno.2017.02.020. Epub 2017 Feb 14.
3
Stage III disease of ovarian, tubal and peritoneal cancers can be accurately diagnosed with pre-operative CT. Japan Clinical Oncology Group Study JCOG0602.术前 CT 可准确诊断卵巢、输卵管和腹膜癌的 III 期疾病。日本临床肿瘤学组研究 JCOG0602。
Jpn J Clin Oncol. 2021 Feb 8;51(2):205-212. doi: 10.1093/jjco/hyaa145.
4
A contemporary analysis of the ability of preoperative serum CA-125 to predict primary cytoreductive outcome in patients with advanced ovarian, tubal and peritoneal carcinoma.术前血清CA-125预测晚期卵巢癌、输卵管癌和腹膜癌患者初次肿瘤细胞减灭术结局能力的当代分析。
Gynecol Oncol. 2009 Jan;112(1):6-10. doi: 10.1016/j.ygyno.2008.10.010.
5
Radiological predictors of cytoreductive outcomes in patients with advanced ovarian cancer.晚期卵巢癌患者细胞减灭术结局的放射学预测指标
BJOG. 2015 May;122(6):843-849. doi: 10.1111/1471-0528.12992. Epub 2014 Aug 5.
6
Follow-up study of the correlation between postoperative computed tomographic scan and primary surgeon assessment in patients with advanced ovarian, tubal, or peritoneal carcinoma reported to have undergone primary surgical cytoreduction to residual disease of 1 cm or smaller.对报告接受过初始手术细胞减灭术,残留病灶为 1cm 或更小的晚期卵巢、输卵管或腹膜癌患者,进行术后计算机断层扫描与初始外科医生评估相关性的随访研究。
Int J Gynecol Cancer. 2010 Apr;20(3):353-7. doi: 10.1111/IGC.0b013e3181d09fd6.
7
Surgical risk score predicts suboptimal debulking or a major perioperative complication in patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer.手术风险评分可预测晚期上皮性卵巢癌、输卵管癌或原发性腹膜癌患者的肿瘤减灭术效果不佳或主要围手术期并发症。
Int J Gynecol Cancer. 2011 Nov;21(8):1422-7. doi: 10.1097/IGC.0b013e31822c7704.
8
Prospective study of the correlation between postoperative computed tomography scan and primary surgeon assessment in patients with advanced ovarian, tubal, and peritoneal carcinoma reported to have undergone primary surgical cytoreduction to residual disease 1 cm or less.对晚期卵巢癌、输卵管癌和腹膜癌患者进行的前瞻性研究,这些患者据报告已接受初次手术细胞减灭术,残余病灶达1厘米或更小,研究内容为术后计算机断层扫描与主刀医生评估之间的相关性。
J Clin Oncol. 2007 Nov 1;25(31):4946-51. doi: 10.1200/JCO.2007.12.2317.
9
Use of ablation and ultrasonic aspiration at primary debulking surgery in advanced stage ovarian, fallopian tube, and primary peritoneal cancer.在晚期卵巢癌、输卵管癌和原发性腹膜癌的初次肿瘤细胞减灭术中使用消融和超声吸引术。
Int J Gynecol Cancer. 2020 Jul;30(7):1052-1057. doi: 10.1136/ijgc-2020-001466. Epub 2020 Jun 2.
10
The utility of computed tomography scans in predicting suboptimal cytoreductive surgery in women with advanced ovarian carcinoma.计算机断层扫描在预测晚期卵巢癌女性患者减瘤手术效果欠佳中的应用。
Cancer. 2004 Jul 15;101(2):346-52. doi: 10.1002/cncr.20376.

引用本文的文献

1
Trends in Surgical Outcomes and Overall Survival Among Women Undergoing Debulking Surgery for Advanced Ovarian Cancer in the U.S: Analysis of the National Cancer Database.美国晚期卵巢癌减瘤手术女性患者的手术结局及总生存率趋势:国家癌症数据库分析
Cancers (Basel). 2025 Sep 2;17(17):2884. doi: 10.3390/cancers17172884.
2
The Influence of Circulating Immune Cell and CA125 Dynamics on Neoadjuvant Therapy Selection for Advanced Ovarian Cancer.循环免疫细胞和 CA125 动态变化对晚期卵巢癌新辅助治疗选择的影响。
Medicina (Kaunas). 2024 Aug 9;60(8):1290. doi: 10.3390/medicina60081290.
3
Construction of a nomogram model for predicting the outcome of debulking surgery for ovarian cancer on the basis of clinical indicators.

本文引用的文献

1
Cancer statistics, 2014.癌症统计数据,2014 年。
CA Cancer J Clin. 2014 Jan-Feb;64(1):9-29. doi: 10.3322/caac.21208. Epub 2014 Jan 7.
2
Survival impact of complete cytoreduction to no gross residual disease for advanced-stage ovarian cancer: a meta-analysis.晚期卵巢癌完全肿瘤细胞减灭术至无肉眼残留病灶对生存的影响:一项荟萃分析。
Gynecol Oncol. 2013 Sep;130(3):493-8. doi: 10.1016/j.ygyno.2013.05.040. Epub 2013 Jun 6.
3
Impact of complete cytoreduction leaving no gross residual disease associated with radical cytoreductive surgical procedures on survival in advanced ovarian cancer.
基于临床指标构建预测卵巢癌肿瘤细胞减灭术预后的列线图模型。
Front Oncol. 2024 Jul 10;14:1421247. doi: 10.3389/fonc.2024.1421247. eCollection 2024.
4
Are preoperative serum cancer antigen 125 levels a prognostic factor for outcome in epithelial ovarian cancer? A systematic review.术前血清癌抗原125水平是上皮性卵巢癌预后的一个因素吗?一项系统评价。
Niger Med J. 2024 May 23;65(2):108-118. doi: 10.60787/nmj-v65i2-418. eCollection 2024 Mar-Apr.
5
Diagnostic accuracy and clinical value of [68Ga]Ga-FAPI-46 PET/CT for staging patients with ovarian cancer: study protocol for a prospective clinical trial.[68Ga]Ga-FAPI-46 PET/CT 诊断卵巢癌患者分期的准确性和临床价值:一项前瞻性临床试验的研究方案。
BMC Cancer. 2024 Jun 7;24(1):699. doi: 10.1186/s12885-024-12461-w.
6
Trends in specific procedures performed at the time of cytoreduction for ovarian cancer: Is interval debulking surgery truly less radical? A Memorial Sloan Kettering Cancer Center Team Ovary study.卵巢癌细胞减灭术时特定手术操作的趋势:间隔性肿瘤细胞减灭术真的不那么激进吗?纪念斯隆凯特琳癌症中心卵巢研究团队。
Gynecol Oncol. 2024 Aug;187:80-84. doi: 10.1016/j.ygyno.2024.05.009. Epub 2024 May 11.
7
Predictive value of the Adult Comorbidity Evaluation 27 on adverse surgical outcomes and survival in elderly with advanced epithelial ovarian cancer undergoing cytoreductive surgery.老年晚期上皮性卵巢癌患者行细胞减灭术后,成人合并症评估 27 对不良手术结局和生存的预测价值。
Eur J Med Res. 2024 Mar 17;29(1):179. doi: 10.1186/s40001-024-01666-1.
8
Neoadjuvant chemotherapy for high-grade serous ovarian cancer: radiologic-pathologic correlation of response assessment and predictors of progression.高级别浆液性卵巢癌的新辅助化疗:反应评估的放射学-病理学相关性及进展预测因素
Abdom Radiol (NY). 2024 Jun;49(6):2040-2048. doi: 10.1007/s00261-024-04215-w. Epub 2024 Mar 13.
9
Developing a novel image marker to predict the clinical outcome of neoadjuvant chemotherapy (NACT) for ovarian cancer patients.开发一种新的图像标志物来预测卵巢癌患者新辅助化疗(NACT)的临床结局。
Comput Biol Med. 2024 Apr;172:108240. doi: 10.1016/j.compbiomed.2024.108240. Epub 2024 Feb 27.
10
Preoperative serum level of CA153 and a new model to predict the sub-optimal primary debulking surgery in patients with advanced epithelial ovarian cancer.术前血清 CA153 水平与新模型预测晚期上皮性卵巢癌患者初次肿瘤细胞减灭术效果不佳。
World J Surg Oncol. 2024 Feb 23;22(1):64. doi: 10.1186/s12957-024-03336-2.
根治性细胞减灭术治疗晚期卵巢癌时完全肿瘤细胞减灭术且无肉眼残留病灶对生存的影响。
Ann Surg Oncol. 2012 Dec;19(13):4059-67. doi: 10.1245/s10434-012-2446-8. Epub 2012 Jul 6.
4
An analysis of patients with bulky advanced stage ovarian, tubal, and peritoneal carcinoma treated with primary debulking surgery (PDS) during an identical time period as the randomized EORTC-NCIC trial of PDS vs neoadjuvant chemotherapy (NACT).分析同期接受根治性手术(PDS)与新辅助化疗(NACT)随机 EORTC-NCIC 试验的大块晚期卵巢、输卵管和腹膜癌患者。
Gynecol Oncol. 2012 Jan;124(1):10-4. doi: 10.1016/j.ygyno.2011.08.014. Epub 2011 Sep 13.
5
Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer.新辅助化疗与初始肿瘤细胞减灭术用于 IIIC 或 IV 期卵巢癌。
N Engl J Med. 2010 Sep 2;363(10):943-53. doi: 10.1056/NEJMoa0908806.
6
Preoperative serum CA-125 levels and risk of suboptimal cytoreduction in ovarian cancer: a meta-analysis.术前血清 CA-125 水平与卵巢癌减瘤不充分风险的关系:一项荟萃分析。
J Surg Oncol. 2010 Jan 1;101(1):13-7. doi: 10.1002/jso.21398.
7
Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a Phase III Trial of the Gynecologic Cancer Intergroup.晚期卵巢癌新型铂类治疗方案的评估:妇科肿瘤协作组的一项III期试验
J Clin Oncol. 2009 Mar 20;27(9):1419-25. doi: 10.1200/JCO.2008.19.1684. Epub 2009 Feb 17.
8
Can the preoperative Ca-125 level predict optimal cytoreduction in patients with advanced ovarian carcinoma? A single institution cohort study.术前Ca-125水平能否预测晚期卵巢癌患者的最佳肿瘤细胞减灭术?一项单机构队列研究。
Gynecol Oncol. 2009 Jan;112(1):11-5. doi: 10.1016/j.ygyno.2008.09.020.
9
A contemporary analysis of the ability of preoperative serum CA-125 to predict primary cytoreductive outcome in patients with advanced ovarian, tubal and peritoneal carcinoma.术前血清CA-125预测晚期卵巢癌、输卵管癌和腹膜癌患者初次肿瘤细胞减灭术结局能力的当代分析。
Gynecol Oncol. 2009 Jan;112(1):6-10. doi: 10.1016/j.ygyno.2008.10.010.
10
Prospective study of the correlation between postoperative computed tomography scan and primary surgeon assessment in patients with advanced ovarian, tubal, and peritoneal carcinoma reported to have undergone primary surgical cytoreduction to residual disease 1 cm or less.对晚期卵巢癌、输卵管癌和腹膜癌患者进行的前瞻性研究,这些患者据报告已接受初次手术细胞减灭术,残余病灶达1厘米或更小,研究内容为术后计算机断层扫描与主刀医生评估之间的相关性。
J Clin Oncol. 2007 Nov 1;25(31):4946-51. doi: 10.1200/JCO.2007.12.2317.